{"nctId":"NCT00614614","briefTitle":"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014","startDateStruct":{"date":"2008-02-13"},"conditions":["Infections, Meningococcal"],"count":1558,"armGroups":[{"label":"Menhibrix 1 Group","type":"EXPERIMENTAL","interventionNames":["Biological: GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)","Biological: GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)","Biological: Infanrix®","Biological: Pediarix®"]},{"label":"ActHIB- Infanrix Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Infanrix®","Biological: ActHIB®","Biological: Pediarix®"]}],"interventions":[{"name":"GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)","otherNames":["Nimenrix"]},{"name":"GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)","otherNames":["Menhibrix"]},{"name":"Infanrix®","otherNames":[]},{"name":"ActHIB®","otherNames":[]},{"name":"Pediarix®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects for whom the investigator believes that parents/guardians can and will comply with the requirements of the protocol.\n* A male or female between, and including, 6 and 12 weeks of age (+ 6 days) at the time of the first vaccination.\n* Written informed consent obtained from the parent or guardian of the subject.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n* Born after 36 weeks gestation.\n* For inclusion in the booster phase, subjects must have received all three doses in the primary phase.\n\nExclusion Criteria:\n\nExclusion criteria for enrolment (primary phase)\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.\n* Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of study vaccine(s).\n* Previous vaccination against Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, and/or poliovirus; more than one previous dose of hepatitis B vaccine.\n* History of Neisseria meningitidis, hepatitis B, Haemophilus influenzae type b, diphtheria, tetanus, polio or pertussis diseases.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, or by dry natural latex rubber.\n* Major congenital defects or serious chronic illness.\n* History of any neurologic disorders or seizures.\n* Acute disease at time of enrollment.\n* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.\n* Concurrent participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).\n\nExclusion criteria for enrolment (booster phase)\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding entry into the booster phase (Visit 4), or planned use during the study period.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.\n* Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of entry into the booster phase (Visit 4) with the exception of Prevnar® and Hib (see the following three criteria) (Note; licensed influenza vaccine is allowed throughout the study)\n* Planned administration/administration of a fourth dose of Prevnar® within 30 days of a booster dose of Infanrix®\n* Previous administration of a booster dose of Hib prior to entry to the booster phase.\n* Previous administration of a primary dose of Hib vaccine that is not part of the study protocol.\n* Previous vaccination against Neisseria meningitidis that is not part of the study protocol.\n* Previous vaccination with diphtheria, tetanus and pertussis antigens outside of the primary phase of the study.\n* History of Neisseria meningitidis, Hib, diphtheria, tetanus or pertussis diseases.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, or by dry natural latex rubber.\n* Major congenital defects or serious chronic illness.\n* History of any neurologic disorders or seizures.\n* Acute disease at time of enrollment.\n* Administration of immunoglobulins and/or any blood products within the past 3 months or planned administration during the study period.\n* Concurrent participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) Antibody Titers for N. Meningitidis Serogroups A(MenA), W-135(MenW-135), C(MenC) and Y(MenY) Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 1 Group","description":"The cut-off values assessed for hSBA-MenA, hSBA-MenW-135, hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:8","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"254","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"286","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"270","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"291","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With hSBA-MenA, hSBA-MenW-135, hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 2 Group","description":"The cut-off values assessed for hSBA-MenA, hSBA-MenW-135, hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:8","classes":[{"categories":[{"measurements":[{"groupId":"OG003","value":"248","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG003","value":"293","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG003","value":"279","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG003","value":"303","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Nimenrix 1 Group","description":"Antibody titers were expressed as Geometric mean titers (GMTs)","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"3845.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"4800.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Nimenrix 2 Group","description":"Antibody titers were expressed as Geometric mean titers (GMTs)","classes":[{"categories":[{"measurements":[{"groupId":"OG003","value":"7230.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG003","value":"7487.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-Diptheria (Anti-D) and Anti-Tetanus (Anti-T) Antibody Concentrations Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 2 Group and ActHIB- Infanrix Group","description":"The cut-off value assessed for Anti-D and Anti-T were greater than or equal to (≥) 1.0 International Units per milliliter (IU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG003","value":"253","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145","spread":null},{"groupId":"OG003","value":"253","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Menhibrix 2 Group","description":"Antibody titers were expressed as Geometric mean titers (GMTs)","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"2676.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"2227.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Value in Menhibrix 2 Group","description":"The cut-off values assessed for hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:8","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"155","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"157","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Antibody Concentrations for Anti-PT (Pertusis Toxoid), Anti-FHA (Filamentous Hemagglutinin) and Anti-PRN (Pertactin) in Nimenrix 2 Group and ActHIB- Infanrix Group","description":"Concentrations were provided as Geometric mean concentrations (GMCs) and expressed as enzyme-linked immunosorbent assay units per milliliter (EL.U/mL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.0","spread":null},{"groupId":"OG003","value":"67.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"422.9","spread":null},{"groupId":"OG003","value":"353.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"315.1","spread":null},{"groupId":"OG003","value":"189.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 1 Group and Menhibrix 2 Group","description":"The cut-off values assessed for hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:4","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"286","spread":null},{"groupId":"OG002","value":"155","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"291","spread":null},{"groupId":"OG002","value":"157","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With hSBA-MenA and hSBA MenW-135 Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 1 Group","description":"The cut-off values assessed for hSBA-MenA and hSBA-MenW-135 were greater than or equal to (≥) 1:4","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"256","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"270","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titers for hSBA-MenA and hSBA MenW-135 in Nimenrix 1 Group","description":"Antibody titers were expressed as Geometric mean titers (GMTs)","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"94.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"923.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Nimenrix 2 Group","description":"Antibody titers were expressed as Geometric mean titers (GMTs)","classes":[{"categories":[{"measurements":[{"groupId":"OG003","value":"67.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG003","value":"142.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 2 Group","description":"The cut-off values assessed for hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:4 and ≥ 1:8","classes":[{"categories":[{"measurements":[{"groupId":"OG003","value":"243","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG003","value":"241","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG003","value":"258","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG003","value":"258","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-D and Anti-T Geometric Mean Antibody Concentrations","description":"Concentrations were provided as Geometric Mean Concentrations(GMCs) and expressed as International Units per milliliter (IU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.259","spread":null},{"groupId":"OG001","value":"7.214","spread":null},{"groupId":"OG002","value":"7.360","spread":null},{"groupId":"OG003","value":"7.458","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.500","spread":null},{"groupId":"OG001","value":"7.400","spread":null},{"groupId":"OG002","value":"8.458","spread":null},{"groupId":"OG003","value":"11.751","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-D and Anti-T Antibody Concentrations Greater Than or Equal to Protocol Specified Cut-off Value","description":"The cut-off value assessed for Anti-D and Anti-T were greater than or equal to (≥) 0.1 International Units per milliliter (IU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"252","spread":null},{"groupId":"OG002","value":"132","spread":null},{"groupId":"OG003","value":"254","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"252","spread":null},{"groupId":"OG002","value":"132","spread":null},{"groupId":"OG003","value":"253","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Concentrations Greater Than or Equal to Protocol Specified Cut-off Value","description":"The cut-off values assessed were greater than or equal to (≥) 5 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"252","spread":null},{"groupId":"OG002","value":"130","spread":null},{"groupId":"OG003","value":"254","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"252","spread":null},{"groupId":"OG002","value":"132","spread":null},{"groupId":"OG003","value":"253","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"251","spread":null},{"groupId":"OG002","value":"132","spread":null},{"groupId":"OG003","value":"253","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Concentrations for Anti-PT, Anti-FHA and Anti-PRN in Nimenrix 1 Group and Menhibrix 2 Group","description":"Concentrations were provided as Geometric mean concentrations (GMCs) and expressed as enzyme-linked immunosorbent assay units per milliliter (EL.U/mL)","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"73.3","spread":null},{"groupId":"OG002","value":"86.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"321.6","spread":null},{"groupId":"OG002","value":"371.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"203.8","spread":null},{"groupId":"OG002","value":"220.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-D and Anti-T Antibody Concentrations Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 1 Group and Menhibrix 2 Group","description":"The cut-off values assessed for Anti-D and Anti-T were greater than or equal to (≥) 1.0 International Units per milliliter (IU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"250","spread":null},{"groupId":"OG002","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"250","spread":null},{"groupId":"OG002","value":"132","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 2 Group","description":"The cut-off values assessed for hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY were greater than or equal to (≥) 1:4","classes":[{"categories":[{"measurements":[{"groupId":"OG003","value":"253","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG003","value":"293","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG003","value":"279","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG003","value":"303","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titers for hSBA-MenA and hSBA-MenW-135 in Nimenrix 2 Group","description":"Antibody titers were expressed as Geometric mean titers (GMTs)","classes":[{"categories":[{"measurements":[{"groupId":"OG003","value":"92.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG003","value":"1582.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) Following Each Dose With Nimenrix or Menhibrix Vaccine","description":"Any was defined as any solicited local symptom reported regardless of intensity grade. Grade 3 redness and swelling was greater than (\\>) 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"156","spread":null},{"groupId":"OG002","value":"104","spread":null},{"groupId":"OG003","value":"170","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"171","spread":null},{"groupId":"OG002","value":"90","spread":null},{"groupId":"OG003","value":"169","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"54","spread":null},{"groupId":"OG003","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs in the Booster Phase","description":"Any fever was defined as axillary temperature greater than or equal to 38.0 degree centigrade i.e ≥38.0°C, grade 3 fever was axillary temperature \\> 40.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a general symptom that prevented normal activity. Related was a general symptom assessed by the investigator as causally related to the study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"171","spread":null},{"groupId":"OG002","value":"97","spread":null},{"groupId":"OG003","value":"161","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"148","spread":null},{"groupId":"OG002","value":"80","spread":null},{"groupId":"OG003","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"230","spread":null},{"groupId":"OG002","value":"128","spread":null},{"groupId":"OG003","value":"218","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"202","spread":null},{"groupId":"OG002","value":"106","spread":null},{"groupId":"OG003","value":"188","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"144","spread":null},{"groupId":"OG002","value":"73","spread":null},{"groupId":"OG003","value":"138","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"115","spread":null},{"groupId":"OG002","value":"55","spread":null},{"groupId":"OG003","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"132","spread":null},{"groupId":"OG002","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"114","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"195","spread":null},{"groupId":"OG002","value":"103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"171","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"117","spread":null},{"groupId":"OG002","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Rash","description":"Examples of rash included hives, idiopathic thrombocytopenic purpura, petechiae.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"93","spread":null},{"groupId":"OG002","value":"54","spread":null},{"groupId":"OG003","value":"83","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) Following Vaccination With Infanrix Vaccine","description":"Any was defined as any solicited local symptom reported regardless of intensity grade. Grade 3 redness and swelling was \\> 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"145","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"175","spread":null},{"groupId":"OG002","value":"102","spread":null},{"groupId":"OG003","value":"171","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"114","spread":null},{"groupId":"OG002","value":"73","spread":null},{"groupId":"OG003","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any New Onset of Chronic Illness (NOCI) and Any Emergency Room (ER) Visits","description":"NOCIs include autoimmune disorders, asthma, type I diabetes and allergies. AEs prompting emergency room visits or physician visits are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"49","spread":null},{"groupId":"OG003","value":"76","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any New Onset of Chronic Illness (NOCI) and Any Emergency Room (ER) Visits","description":"NOCIs include autoimmune disorders, asthma, type I diabetes and allergies. AEs prompting emergency room visits or physician visits are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"293","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the First or Single Booster Phase Vaccination","description":"Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"194","spread":null},{"groupId":"OG002","value":"105","spread":null},{"groupId":"OG003","value":"182","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Unsolicited AEs in Nimenrix 1 Group and Menhibrix 2 Group After the Second Booster Phase Vaccination","description":"Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"167","spread":null},{"groupId":"OG002","value":"79","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":58,"n":1272},"commonTop":["Irritability","Redness","Drowsiness","Pain","Pain"]}}}